IRIS Accounts Production v26.3.0.614 11938276 Board of Directors 1.5.25 30.4.26 30.4.26 false true false false true false 46333 50766 137665 125237 97042 120804 5710 46333 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh119382762025-04-30119382762026-04-30119382762025-05-012026-04-30119382762024-04-30119382762024-05-012025-04-30119382762025-04-3011938276ns15:EnglandWales2025-05-012026-04-3011938276ns14:PoundSterling2025-05-012026-04-3011938276ns10:Director12025-05-012026-04-3011938276ns10:PrivateLimitedCompanyLtd2025-05-012026-04-3011938276ns10:SmallEntities2025-05-012026-04-3011938276ns10:AuditExempt-NoAccountantsReport2025-05-012026-04-3011938276ns10:SmallCompaniesRegimeForDirectorsReport2025-05-012026-04-3011938276ns10:SmallCompaniesRegimeForAccounts2025-05-012026-04-3011938276ns10:FullAccounts2025-05-012026-04-301193827642ns10:Director22025-04-301193827642ns10:Director22024-04-301193827642ns10:Director22025-05-012026-04-301193827642ns10:Director22024-05-012025-04-301193827642ns10:Director22026-04-301193827642ns10:Director22025-04-3011938276ns10:Director22025-05-012026-04-3011938276ns10:RegisteredOffice2025-05-012026-04-3011938276ns5:CurrentFinancialInstruments2026-04-3011938276ns5:CurrentFinancialInstruments2025-04-3011938276ns5:ShareCapital2026-04-3011938276ns5:ShareCapital2025-04-3011938276ns5:FurtherSpecificReserve3ComponentTotalEquity2026-04-3011938276ns5:FurtherSpecificReserve3ComponentTotalEquity2025-04-3011938276ns5:RetainedEarningsAccumulatedLosses2026-04-3011938276ns5:RetainedEarningsAccumulatedLosses2025-04-3011938276ns5:PlantMachinery2025-05-012026-04-3011938276ns5:PlantMachinery2025-04-3011938276ns5:PlantMachinery2026-04-3011938276ns5:PlantMachinery2025-04-3011938276ns5:CostValuation2025-04-3011938276ns5:AdditionsToInvestments2026-04-3011938276ns5:DisposalsRepaymentsInvestments2026-04-3011938276ns5:RevaluationsIncreaseDecreaseInInvestments2026-04-3011938276ns5:CostValuation2026-04-3011938276ns5:WithinOneYearns5:CurrentFinancialInstruments2026-04-3011938276ns5:WithinOneYearns5:CurrentFinancialInstruments2025-04-3011938276ns5:FurtherSpecificReserve3ComponentTotalEquity2025-04-3011938276ns10:Director112025-04-3011938276ns10:Director112024-04-3011938276ns10:Director112025-05-012026-04-3011938276ns10:Director112024-05-012025-04-3011938276ns10:Director112026-04-3011938276ns10:Director112025-04-30
REGISTERED NUMBER: 11938276 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2026

FOR

WAWRUCH PATHOLOGY SERVICES LIMITED

WAWRUCH PATHOLOGY SERVICES LIMITED (REGISTERED NUMBER: 11938276)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


WAWRUCH PATHOLOGY SERVICES LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 APRIL 2026







DIRECTORS: Dr P Wawruch
Mrs J Wawruch





REGISTERED OFFICE: 6 Nine Acres
Ipswich
Suffolk
IP2 0DL





REGISTERED NUMBER: 11938276 (England and Wales)





ACCOUNTANTS: LFM
Chartered Certified Accountants
The Stables
23b Lenten Street
Alton
Hampshire
GU34 1HG

WAWRUCH PATHOLOGY SERVICES LIMITED (REGISTERED NUMBER: 11938276)

BALANCE SHEET
30 APRIL 2026

2026 2025
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 61,488 13,528
Investments 5 37,994 35,201
99,482 48,729

CURRENT ASSETS
Debtors 6 51,621 91,818
Cash at bank 1 97
51,622 91,915
CREDITORS
Amounts falling due within one year 7 17,161 76,921
NET CURRENT ASSETS 34,461 14,994
TOTAL ASSETS LESS CURRENT
LIABILITIES

133,943

63,723

PROVISIONS FOR LIABILITIES 14,005 3,325
NET ASSETS 119,938 60,398

CAPITAL AND RESERVES
Called up share capital 102 102
Fair value reserve 8 - 173
Retained earnings 119,836 60,123
SHAREHOLDERS' FUNDS 119,938 60,398

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

WAWRUCH PATHOLOGY SERVICES LIMITED (REGISTERED NUMBER: 11938276)

BALANCE SHEET - continued
30 APRIL 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 November 2026 and were signed on its behalf by:





Dr P Wawruch - Director


WAWRUCH PATHOLOGY SERVICES LIMITED (REGISTERED NUMBER: 11938276)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

1. STATUTORY INFORMATION

Wawruch Pathology Services Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 20% straight line and 20% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2025 - 2 ) .

WAWRUCH PATHOLOGY SERVICES LIMITED (REGISTERED NUMBER: 11938276)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2026

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 May 2025 41,772
Additions 63,322
Disposals (25,640 )
At 30 April 2026 79,454
DEPRECIATION
At 1 May 2025 28,244
Charge for year 13,354
Eliminated on disposal (23,632 )
At 30 April 2026 17,966
NET BOOK VALUE
At 30 April 2026 61,488
At 30 April 2025 13,528

5. FIXED ASSET INVESTMENTS
Other
investments
£   
COST OR VALUATION
At 1 May 2025 35,201
Additions 154,705
Disposals (151,627 )
Revaluations (285 )
At 30 April 2026 37,994
NET BOOK VALUE
At 30 April 2026 37,994
At 30 April 2025 35,201

Cost or valuation at 30 April 2026 is represented by:

Other
investments
£   
Valuation in 2026 37,994

WAWRUCH PATHOLOGY SERVICES LIMITED (REGISTERED NUMBER: 11938276)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2026

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade debtors 50,913 58,535
Other debtors 708 33,283
51,621 91,818

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Taxation and social security 9,573 28,759
Other creditors 7,588 48,162
17,161 76,921

8. RESERVES
Fair
value
reserve
£   
At 1 May 2025 173
Value to fair value reserve (173 )

At 30 April 2026 -

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 30 April 2026 and 30 April 2025:

2026 2025
£    £   
Dr P Wawruch and Mrs J Wawruch
Balance outstanding at start of year (46,333 ) (50,766 )
Amounts advanced 137,665 125,237
Amounts repaid (97,042 ) (120,804 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (5,710 ) (46,333 )

Interest on the overdrawn directors loan has been charged at 2.25% per annum.

10. ULTIMATE CONTROLLING PARTY

The controlling party is Dr P Wawruch.